Published in Drug Week, April 23rd, 2004
The company received approval from the U.S. Food and Drug Administration on March 4 to market the Taxus system in the United States, and it recorded its first sale on March 8.
Preliminary net sales from March 8 through March 19 (10 selling days) were approximately $42 million. At its February 23rd analyst meeting, the company estimated Taxus system sales of between $52 million and $75 million for the period of March 1 through March 31 (23 selling days).
The company estimates the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.